spacer
home > ebr > summer 2003 > smi conference london march 2003, biologics: overcoming the challenges of development and manufacture
PUBLICATIONS
European Biopharmaceutical Review

SMi Conference London March 2003, Biologics: Overcoming the Challenges of Development and Manufacture

The SMi conference was opened by Dr David Glover, Chief Medical Officer at Cambridge Antibody Technology, who outlined the key challenges for biologics manufacture today: the predicted shortage of manufacturing capacity, the decision to outsource or make in-house, and technical and regulatory challenges.

It is predicted that just 10 monoclonal antibody (mabs) products would consume 75 per cent of the worlds' biologic manufacturing capacity and yet there are 60 mabs likely to emerge onto the market in the next one to seven years. However, the estimate of 400 mabs in clinical trial, which is often quoted, is probably an overestimate, as a single mab can be in clinical trial for a number of different clinical indications. This reduces the current estimate from 400 to around 100. Whilst currently, 30 per cent of FDA drug applications are for biotech drugs, a curious statistic is that biologics produced by pharma/biotech alliances have a 70 per cent greater chance of receiving FDA approval. It is not known whether this is a synergistic effort of the companies working together or if biologic drugs are more likely to get FDA approval than chemical entity-based drugs.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Keith Chidwick, Consultant at Technomark Consulting Services Ltd
spacer
Keith Chidwick
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Organization Updates

Philadelphia, PA – May 20, 2019 – PCI Pharma Services, a leading biopharmaceutical outsourcing services provider, is pleased to announce the following management updates to help drive the company’s future vision, strategy and growth.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 
Industry Events

Multimodal 2019

18-20 June 2019, NEC, Birmingham, UK

Now in its twelfth year, Multimodal is the UK and Ireland’s premier freight transport, logistics and supply chain management event.  Shippers and cargo owners attend to improve their businesses; by finding ways of moving their products more efficiently and by meeting new suppliers. 
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement